カテゴリー： 世界, 医療/バイオ, QYResearch

神経変性疾患治療薬の世界市場インサイト・予測（～2028年）

【英語タイトル】Global Neurodegenerative Diseases Therapeutics Market Insights, Forecast to 2028

QYResearchが出版した調査資料（QY22JLX09259）・商品コード：QY22JLX09259
・発行会社（調査会社）：QYResearch
・発行日：2022年7月（※2025年版があります。お問い合わせください。）
・ページ数：112
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

COVID-19のパンデミックにより、神経変性疾患治療薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に神経変性疾患治療薬の世界市場のxxx％を占める「多発性硬化症治療薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「子供」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
神経変性疾患治療薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの神経変性疾患治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

神経変性疾患治療薬のグローバル主要企業には、AB Science SA、AbbVie Inc.、Acadia Pharmaceuticals Inc.、Biogen Inc.、F. Hoffmann La Roche Ltd.、H Lundbeck AS、Mitsubishi Chemical Holdings Corp.、Novartis AG、Sanofi、Teva Pharmaceutical Industries Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

神経変性疾患治療薬市場は、種類と用途によって区分されます。世界の神経変性疾患治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
多発性硬化症治療薬、アルツハイマー病治療薬、パーキンソン病治療薬、パーキンソン病治療薬、その他

【用途別セグメント】
子供、成人

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 神経変性疾患治療薬製品概要
- 種類別市場（多発性硬化症治療薬、アルツハイマー病治療薬、パーキンソン病治療薬、パーキンソン病治療薬、その他）
- 用途別市場（子供、成人）
- 調査の目的
・エグゼクティブサマリー
- 世界の神経変性疾患治療薬販売量予測2017-2028
- 世界の神経変性疾患治療薬売上予測2017-2028
- 神経変性疾患治療薬の地域別販売量
- 神経変性疾患治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別神経変性疾患治療薬販売量
- 主要メーカー別神経変性疾患治療薬売上
- 主要メーカー別神経変性疾患治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（多発性硬化症治療薬、アルツハイマー病治療薬、パーキンソン病治療薬、パーキンソン病治療薬、その他）
- 神経変性疾患治療薬の種類別販売量
- 神経変性疾患治療薬の種類別売上
- 神経変性疾患治療薬の種類別価格
・用途別市場規模（子供、成人）
- 神経変性疾患治療薬の用途別販売量
- 神経変性疾患治療薬の用途別売上
- 神経変性疾患治療薬の用途別価格
・北米市場
- 北米の神経変性疾患治療薬市場規模（種類別、用途別）
- 主要国別の神経変性疾患治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの神経変性疾患治療薬市場規模（種類別、用途別）
- 主要国別の神経変性疾患治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の神経変性疾患治療薬市場規模（種類別、用途別）
- 主要国別の神経変性疾患治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の神経変性疾患治療薬市場規模（種類別、用途別）
- 主要国別の神経変性疾患治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの神経変性疾患治療薬市場規模（種類別、用途別）
- 主要国別の神経変性疾患治療薬市場規模（トルコ、サウジアラビア）
・企業情報
AB Science SA、AbbVie Inc.、Acadia Pharmaceuticals Inc.、Biogen Inc.、F. Hoffmann La Roche Ltd.、H Lundbeck AS、Mitsubishi Chemical Holdings Corp.、Novartis AG、Sanofi、Teva Pharmaceutical Industries Ltd
・産業チェーン及び販売チャネル分析
- 神経変性疾患治療薬の産業チェーン分析
- 神経変性疾患治療薬の原材料
- 神経変性疾患治療薬の生産プロセス
- 神経変性疾患治療薬の販売及びマーケティング
- 神経変性疾患治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 神経変性疾患治療薬の産業動向
- 神経変性疾患治療薬のマーケットドライバー
- 神経変性疾患治療薬の課題
- 神経変性疾患治療薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global Neurodegenerative Diseases Therapeutics Market
The global Neurodegenerative Diseases Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Multiple Sclerosis Therapeutics accounting for % of the Neurodegenerative Diseases Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Child segment is altered to an % CAGR throughout this forecast period.
China Neurodegenerative Diseases Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Neurodegenerative Diseases Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Neurodegenerative Diseases Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Diseases Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Diseases Therapeutics market.
Global Neurodegenerative Diseases Therapeutics Scope and Market Size
Neurodegenerative Diseases Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Multiple Sclerosis Therapeutics
Alzheimer’s Disease Therapeutics
Parkinson’s Disease Therapeutics
Parkinson’s Disease Therapeutics
Others
Segment by Application
Child
Aldult
By Company
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Multiple Sclerosis Therapeutics
1.2.3 Alzheimer’s Disease Therapeutics
1.2.4 Parkinson’s Disease Therapeutics
1.2.5 Parkinson’s Disease Therapeutics
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Child
1.3.3 Aldult
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Therapeutics Market Perspective (2017-2028)
2.2 Neurodegenerative Diseases Therapeutics Growth Trends by Region
2.2.1 Neurodegenerative Diseases Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neurodegenerative Diseases Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Neurodegenerative Diseases Therapeutics Market Dynamics
2.3.1 Neurodegenerative Diseases Therapeutics Industry Trends
2.3.2 Neurodegenerative Diseases Therapeutics Market Drivers
2.3.3 Neurodegenerative Diseases Therapeutics Market Challenges
2.3.4 Neurodegenerative Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Therapeutics Revenue
3.4 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Therapeutics Revenue in 2021
3.5 Neurodegenerative Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2023-2028)
5 Neurodegenerative Diseases Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
6.2 North America Neurodegenerative Diseases Therapeutics Market Size by Type
6.2.1 North America Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Application
6.3.1 North America Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
6.4 North America Neurodegenerative Diseases Therapeutics Market Size by Country
6.4.1 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
7.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Type
7.2.1 Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Application
7.3.1 Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
7.4 Europe Neurodegenerative Diseases Therapeutics Market Size by Country
7.4.1 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
9.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Type
9.2.1 Latin America Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Neurodegenerative Diseases Therapeutics Market Size by Application
9.3.1 Latin America Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country
9.4.1 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AB Science SA
11.1.1 AB Science SA Company Details
11.1.2 AB Science SA Business Overview
11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction
11.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.1.5 AB Science SA Recent Developments
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Details
11.2.2 AbbVie Inc. Business Overview
11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction
11.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.2.5 AbbVie Inc. Recent Developments
11.3 Acadia Pharmaceuticals Inc.
11.3.1 Acadia Pharmaceuticals Inc. Company Details
11.3.2 Acadia Pharmaceuticals Inc. Business Overview
11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction
11.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.3.5 Acadia Pharmaceuticals Inc. Recent Developments
11.4 Biogen Inc.
11.4.1 Biogen Inc. Company Details
11.4.2 Biogen Inc. Business Overview
11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction
11.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.4.5 Biogen Inc. Recent Developments
11.5 F. Hoffmann La Roche Ltd.
11.5.1 F. Hoffmann La Roche Ltd. Company Details
11.5.2 F. Hoffmann La Roche Ltd. Business Overview
11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction
11.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.5.5 F. Hoffmann La Roche Ltd. Recent Developments
11.6 H Lundbeck AS
11.6.1 H Lundbeck AS Company Details
11.6.2 H Lundbeck AS Business Overview
11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction
11.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.6.5 H Lundbeck AS Recent Developments
11.7 Mitsubishi Chemical Holdings Corp.
11.7.1 Mitsubishi Chemical Holdings Corp. Company Details
11.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction
11.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.7.5 Mitsubishi Chemical Holdings Corp. Recent Developments
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction
11.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.8.5 Novartis AG Recent Developments
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.9.5 Sanofi Recent Developments
11.10 Teva Pharmaceutical Industries Ltd
11.10.1 Teva Pharmaceutical Industries Ltd Company Details
11.10.2 Teva Pharmaceutical Industries Ltd Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.10.5 Teva Pharmaceutical Industries Ltd Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Multiple Sclerosis Therapeutics
Table 3. Key Players of Alzheimer's Disease Therapeutics
Table 4. Key Players of Parkinson's Disease Therapeutics
Table 5. Key Players of Parkinson's Disease Therapeutics
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2017-2022)
Table 11. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2023-2028)
Table 13. Neurodegenerative Diseases Therapeutics Market Trends
Table 14. Neurodegenerative Diseases Therapeutics Market Drivers
Table 15. Neurodegenerative Diseases Therapeutics Market Challenges
Table 16. Neurodegenerative Diseases Therapeutics Market Restraints
Table 17. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Therapeutics Revenue Share by Players (2017-2022)
Table 19. Global Top Neurodegenerative Diseases Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2021)
Table 20. Ranking of Global Top Neurodegenerative Diseases Therapeutics Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Diseases Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2017-2022)
Table 28. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2023-2028)
Table 30. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Therapeutics Revenue Share by Application (2017-2022)
Table 32. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Neurodegenerative Diseases Therapeutics Revenue Share by Application (2023-2028)
Table 34. North America Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 64. AB Science SA Company Details
Table 65. AB Science SA Business Overview
Table 66. AB Science SA Neurodegenerative Diseases Therapeutics Product
Table 67. AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 68. AB Science SA Recent Developments
Table 69. AbbVie Inc. Company Details
Table 70. AbbVie Inc. Business Overview
Table 71. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product
Table 72. AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 73. AbbVie Inc. Recent Developments
Table 74. Acadia Pharmaceuticals Inc. Company Details
Table 75. Acadia Pharmaceuticals Inc. Business Overview
Table 76. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product
Table 77. Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 78. Acadia Pharmaceuticals Inc. Recent Developments
Table 79. Biogen Inc. Company Details
Table 80. Biogen Inc. Business Overview
Table 81. Biogen Inc. Neurodegenerative Diseases Therapeutics Product
Table 82. Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 83. Biogen Inc. Recent Developments
Table 84. F. Hoffmann La Roche Ltd. Company Details
Table 85. F. Hoffmann La Roche Ltd. Business Overview
Table 86. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product
Table 87. F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 88. F. Hoffmann La Roche Ltd. Recent Developments
Table 89. H Lundbeck AS Company Details
Table 90. H Lundbeck AS Business Overview
Table 91. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product
Table 92. H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 93. H Lundbeck AS Recent Developments
Table 94. Mitsubishi Chemical Holdings Corp. Company Details
Table 95. Mitsubishi Chemical Holdings Corp. Business Overview
Table 96. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product
Table 97. Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 98. Mitsubishi Chemical Holdings Corp. Recent Developments
Table 99. Novartis AG Company Details
Table 100. Novartis AG Business Overview
Table 101. Novartis AG Neurodegenerative Diseases Therapeutics Product
Table 102. Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 103. Novartis AG Recent Developments
Table 104. Sanofi Company Details
Table 105. Sanofi Business Overview
Table 106. Sanofi Neurodegenerative Diseases Therapeutics Product
Table 107. Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 108. Sanofi Recent Developments
Table 109. Teva Pharmaceutical Industries Ltd Company Details
Table 110. Teva Pharmaceutical Industries Ltd Business Overview
Table 111. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product
Table 112. Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 113. Teva Pharmaceutical Industries Ltd Recent Developments
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Diseases Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Multiple Sclerosis Therapeutics Features
Figure 3. Alzheimer's Disease Therapeutics Features
Figure 4. Parkinson's Disease Therapeutics Features
Figure 5. Parkinson's Disease Therapeutics Features
Figure 6. Others Features
Figure 7. Global Neurodegenerative Diseases Therapeutics Market Share by Application: 2021 VS 2028
Figure 8. Child Case Studies
Figure 9. Aldult Case Studies
Figure 10. Neurodegenerative Diseases Therapeutics Report Years Considered
Figure 11. Global Neurodegenerative Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Neurodegenerative Diseases Therapeutics Market Share by Region: 2021 VS 2028
Figure 14. Global Neurodegenerative Diseases Therapeutics Market Share by Players in 2021
Figure 15. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2021
Figure 17. North America Neurodegenerative Diseases Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 18. North America Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2017-2028)
Figure 19. North America Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2017-2028)
Figure 20. North America Neurodegenerative Diseases Therapeutics Market Size Share by Country (2017-2028)
Figure 21. United States Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Neurodegenerative Diseases Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 24. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2017-2028)
Figure 25. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2017-2028)
Figure 26. Europe Neurodegenerative Diseases Therapeutics Market Size Share by Country (2017-2028)
Figure 27. Germany Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2017-2028)
Figure 35. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2017-2028)
Figure 36. Asia Pacific Neurodegenerative Diseases Therapeutics Market Size Share by Region (2017-2028)
Figure 37. China Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Japan Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. South Korea Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. India Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Australia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 43. Latin America Neurodegenerative Diseases Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 44. Latin America Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2017-2028)
Figure 45. Latin America Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2017-2028)
Figure 46. Latin America Neurodegenerative Diseases Therapeutics Market Size Share by Country (2017-2028)
Figure 47. Mexico Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Brazil Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 50. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2017-2028)
Figure 51. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2017-2028)
Figure 52. Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size Share by Country (2017-2028)
Figure 53. Turkey Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. UAE Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. AB Science SA Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 57. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 58. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 59. Biogen Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 60. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 61. H Lundbeck AS Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 62. Mitsubishi Chemical Holdings Corp. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 63. Novartis AG Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 64. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 65. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed


★調査レポート[神経変性疾患治療薬の世界市場インサイト・予測（～2028年）] (コード：QY22JLX09259)販売に関する免責事項を必ずご確認ください。
★調査レポート[神経変性疾患治療薬の世界市場インサイト・予測（～2028年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • ペット治療の世界市場インサイト・予測（～2028年）
  • 脳卒中治療の世界市場インサイト・予測（～2028年）
  • タンパク質＆ペプチド治療薬の世界市場インサイト・予測（～2028年）
  • アンチセンスオリゴヌクレオチド（ASO）治療薬の世界市場インサイト・予測（～2028年）
  • 閉経後膣萎縮治療薬の世界市場インサイト・予測（～2028年）

    • ◆H&Iグローバルリサーチのお客様（例）◆